Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Cybereason, a leading global cybersecurity company, today announced the launch of a new Vulnerability Management product, a ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

The aftermath of the Michelin Guide ceremony has stoked various reactions of but everyone should not miss the forest for the trees ...

Over the 3 to 12 months following catheter ablation, patients who received metformin had greater freedom from recurrent ...

AbbVie and Calico first inked their partnership in 2014 with up to $1.5 billion in funding to advance therapies for diseases, ...

AnaptysBio plans to advance rosnilimab for RA, with a program update expected in the first half of 2026. Read why ANAB stock ...

Robots and cobots are vital to supply chain work, but they are only part of the equation.

Brigham and Women's Hospital's TIMI Study Group reports that in patients with prior ischemic stroke, very low achieved ...

NEW ORLEANS -- Patients experiencing major heart attacks had a lower risk of serious complications if they received a single ...